Aclaris Therapeutics Receives Fast Track Designation for Modzatinib for Moderate to Severe Lichen Planus Life Science Investing
Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada Life Science Investing
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Life Science Investing
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Life Science Investing
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress Life Science Investing
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium Life Science Investing
Rain Enhancement Technologies Signs Exclusive Agreement with UASIT to Deploy WETA Platform in Türkiye Life Science Investing
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors Life Science Investing
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates Life Science Investing
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results Life Science Investing
